A laboratory-made peptide designed to force worn-out cells refusing to die into self-destruction, sparing healthy cells. It does this repeatedly in cell cultures; in aging mice it is linked to better fur, movement, kidney filtering, arteries and hormone output. No person has received it in a registered study, no human dose exists, and it is sold as a research chemical. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Platelet count | 200–350 × 10⁹/L | Detects the class toxicity the peptide is reported not to cause |
| eGFR | >90 mL/min/1.73 m² | Most improved organ function in animals; peptide concentrates there |
| Creatinine | 0.7–1.0 mg/dL (men), 0.6–0.9 mg/dL (women) | Fell with treatment in aged mice |
| Blood urea nitrogen | 10–16 mg/dL | Primary rodent endpoint for renal filtering |
| Alanine aminotransferase and aspartate aminotransferase | ALT 10–26 U/L, AST 10–26 U/L | Peptide prevented liver injury in mice; a rise is off-mechanism |
| hs-CRP | <0.5 mg/L | Tracks systemic inflammation that senescent-cell clearance is meant to reduce |
| Interleukin-6 | <1.5 pg/mL | Fell in treated mouse tissue |
| Total and free testosterone | Total 600–900 ng/dL, free 15–25 pg/mL (men) | Only endocrine function restored in aged animals |
| Urine albumin-to-creatinine ratio | <10 mg/g | Detects glomerular damage before eGFR moves |
| p16INK4a expression in peripheral T cells | No consensus range; only change from own baseline | Closest direct measure of senescent-cell burden |
| Epigenetic age estimate | Epigenetic age below chronological age | Composite readout if senescent-cell clearance influences biological aging |
Cadence: Full baseline panel before exposure; safety subset 2–4 weeks after a cycle; inflammatory and functional markers at 3 months; full panel every 6–12 months or before each cycle.